

IFW

Atty. Dkt. No. 034827-1501

CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage

as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria,

Virginia 22313-1450, on the date below.

## IN THE UNITED STATES PERFECT AND TRADEMARK OFFICE

Applicant:

Huang, et al.

Title:

**METHODS AND** 

COMPOSITIONS FOR THE

AMPLIFICATION OF MUTATIONS IN THE DIAGNOSIS OF CYSTIC

**FIBROSIS** 

Appl. No.:

10/659,582

Filing Date:

09/09/2003

Examiner:

Unknown

Art Unit:

Unknown

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document, except as noted below, is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this

application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

## TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

## RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check

being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

1/2

FOLEY & LARDNER LLP Customer Number: 30542

Telephone: (8

(858) 847-6722

Facsimile:

(858) 792-6773

Barry S. Wilson

Attorney for Applicant Registration No. 39,431

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

s are required to espond to a collection of information unless it contains a valid OMB control Under the Paperwork Reduction Act of 1995, no per

JUN 1 4 2004

Substitute for form 1449B/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** 10/659,582 STATEMENT BY APPLICANT **Filing Date** 09/09/2003 **First Named Inventor** Dong Hui Huang Group Art Unit 1637 (use as many sheets as necessary) **Examiner Name** Unknown 2 of Sheet 1 Attorney Docket Number 034827-1501

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant
		Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
	A1	4,582,788		Erlich	04-15-1986	
	A2	4,683,194		Saiki et al.	07-28-1987	
	A3	4,683,202		Mullis	07-28-1987	
	A4	4,998,617		Ladd et al.	03-12-1991	
	A5	5,130,238		Malek et al.	07-14-1992	
	A6	5,169,766		Schuster et al.	12-08-1992	
	A7	5,846,710		Bajaj	12-08-1998	
	A8	5,885,775		Haff et al.	03-23-1999	
	A9	5,888,819		Goelet et al.	03-30-1999	
	A10	5,955,377		Maul et al.	09-21-1999	
	A11	5,981,178		Tsui et al.	11-09-1999	
	A12	6,011,588		Kim	01-04-2000	
	A13	6,288,220		Kambara et al.	09-11-2001	
	A14	6,355,429		Nygren et al.	03-12-2002	
	A15	6,403,320		Read et al.	06-11-2002	
	A16	6,406,844		Pirrung et al.	06-18-2002	
						•

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	For Office <sup>3</sup>	reign Patent D	Ocument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	A17	WO	88/10315		Siska Diagnostics, Inc.	12-29-1988		
	A18	WO	89/06700		Genentech, Inc.	07-27-1989		-

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T			
	A19	Flanigan et al. "Rapid direct sequence analysis of the dystrophin gene." Am J Hum Genet. 2003 Apr;72(4):931-9.				

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

<sup>1</sup> Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for	form 1449B/	PTO	Complete if Known		
	INFORMATIO	N DISCLO	SURE	Application Number	10/659,582	
	STATEMENT	BY APPLI	CANT	Filing Date	09/09/2003	
				First Named Inventor	Dong Hui Huang	
				Group Art Unit	1637	
	(use as many sh	eets as ne	cessary)	Examiner Name	Unknown	
Sheet	2	of	2	Attorney Docket Number	034827-1501	

Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					
A20	Hoogendoorn, B. et al., "Genotyping Single Nucleotide Polymorphism by Primer Extension and High Performance Liquid Chromatography "Human Genetics (1999) 104:89-93					
A21	Jenison et al., Use of a thin film biosensor for rapid visual detection of PCR products in a multiplex format." Biosens Bioelectron. 16(9-12):757-63 (2001)					
A22	Kwoh, D. et al., Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hydridization format." Proc. Natl. Acad. Sci. (U.S.A.) 86:1173 (1989)					
A23	Landegren, U. et al. "A ligase-mediated gene detection technique." (1988) Science 241:1077-1080					
A24	Mullis, K. et al., "Specific enzymatic amplification of DNA in Vitro: The Polymerase chain reaction." Cold Spring Harbor Symp. Quant. Biol. 51:263-273 (1986)					
A25	Nickerson et al., "Automated DNA diagnostics using an ELISA-based oligonucleotide ligation assay." (1990) Proc. Natl. Acad. Sci. U.S.A. 87:8923-8927					
A26	Piggee, C. et al. "Capillary Electrophoresis for the Detection of Known Point Mutations by Single- Nucleotide Primer Extension and Laser-Induced Fluorescence Detection" Journal of Chromatography A 781 (1997), p. 367-375					
A27	Poddar "Symmetric vs asymmetric PCR and molecular beacon probe in the detection of a target gene of adenovirus." <i>Molec. And Cell. Probes</i> 14:25-32 (2000)					
A28	Walker, G. T. et al., "Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system." Proc. Natl. Acad. Sci. (U.S.A.) 89:392-396 (1992)					
A29	Wall et al. "A 31-mutation assay for cystic fibrosis testing in the clinical molecular diagnostics laboratory." Human Mutation 5:333-338, 1995.					
	A20 A21 A22 A23 A24 A25 A26 A27	item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.  A20 Hoogendoorn, B. et al., "Genotyping Single Nucleotide Polymorphism by Primer Extension and High Performance Liquid Chromatography " Human Genetics (1999) 104:89-93  A21 Jenison et al., Use of a thin film biosensor for rapid visual detection of PCR products in a multiplex format." Biosens Bioelectron. 16(9-12):757-63 (2001)  A22 Kwoh, D. et al., Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hydridization format." Proc. Natl. Acad. Sci. (U.S.A.) 86:1173 (1989)  A23 Landegren, U. et al. "A ligase-mediated gene detection technique." (1988) Science 241:1077-1080  A24 Mullis, K. et al., "Specific enzymatic amplification of DNA in Vitro: The Polymerase chain reaction." Cold Spring Harbor Symp. Quant. Biol. 51:263-273 (1986)  A25 Nickerson et al., "Automated DNA diagnostics using an ELISA-based oligonucleotide ligation assay." (1990) Proc. Natl. Acad. Sci. U.S.A. 87:8923-8927  A26 Piggee, C. et al. "Capillary Electrophoresis for the Detection of Known Point Mutations by Single-Nucleotide Primer Extension and Laser-Induced Fluorescence Detection" Journal of Chromatography A 781 (1997), p. 367-375  A27 Poddar "Symmetric vs asymmetric PCR and molecular beacon probe in the detection of a target gene of adenovirus." Molec. And Cell. Probes 14:25-32 (2000)  A28 Walker, G. T. et al., "Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system." Proc. Natl. Acad. Sci. (U.S.A.) 89:392-396 (1992)				

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.